NCT00508742View on ClinicalTrials.gov

Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization

PHASE3CompletedINTERVENTIONAL
Enrollment

1,866

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

13-valent Pneumococcal Conjugate Vaccine

1 dose at 2, 4, 6 and 12 months of age

BIOLOGICAL

7 valent pneumococcal conjugate vaccine

1 dose at 2, 4, 6 and 12 months of age

Trial Locations (5)

84101

Pfizer Investigational Sites (7), Beersheba

Unknown

Pfizer Investigational Site, Shaqib al-Salam

Pfizer Investigational Site, Ksaife

Pfizer Investigational Site, Rahat

Pfizer Investigational Site, Rahat A

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00508742 - Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization | Biotech Hunter | Biotech Hunter